The JAK2 V617F mutation, first described in 2005, has become an important diagnostic criterion in Philadelphia chromosome negative myeloproliferative diseases, especially in polycythemia vera (PV) [1]–[4]. This evidence concerns the gene JAK2 and acquired polycythemia vera.